A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
- Status
- COMPLETED
- Phase
- PHASE2
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL
- Status
- UNKNOWN
- Phase
- PHASE2
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
CURATE.AI Optimized Modulation for Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
- Status
- TERMINATED
- Phase
- PHASE2
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3